BRPI0407101A - Vacinas meningocócicas mucosais - Google Patents

Vacinas meningocócicas mucosais

Info

Publication number
BRPI0407101A
BRPI0407101A BR0407101-8A BRPI0407101A BRPI0407101A BR PI0407101 A BRPI0407101 A BR PI0407101A BR PI0407101 A BRPI0407101 A BR PI0407101A BR PI0407101 A BRPI0407101 A BR PI0407101A
Authority
BR
Brazil
Prior art keywords
mucosal
compositions
delivery
chitosan
conjugated
Prior art date
Application number
BR0407101-8A
Other languages
English (en)
Inventor
Giuseppe Del Giudice
Barbara Baudner
Original Assignee
Chiron Srl
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Srl, Univ Leiden filed Critical Chiron Srl
Priority claimed from PCT/IB2004/000673 external-priority patent/WO2004067033A1/en
Publication of BRPI0407101A publication Critical patent/BRPI0407101A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"VACINAS MENINGOCóCICAS MUCOSAIS". A invenção proporciona composições imunogênicas para distribuição mucosal compreendendo sacarídeos capsulares de pelo menos dois sorogrupos A, C, W135 e Y de N. meningitidis. é preferido que os sacarídeos capsulares nas composições da invenção sejam conjugados a proteína (s) veículo e/ou sejam oligossacarídeos. Antígenos de oligossacarídeo conjugados são particularmente preferidos. A invenção também proporciona composições imunogênicas compreendendo (a) um antígeno de sacarídeo capsular do sorogrupo C de N. meningitidis e (b) um adjuvante de quitosana. A composição compreende, de preferência, (c) um ou mais de outros antígenos e/ou (d) um ou mais de outros adjuvantes. As composições são particularmente adequadas para distribuição mucosal, incluindo distribuição intranasal. O uso de quitosana e/ou adjuvantes de toxina de ADP-ribosilação destoxificada intensifica as respostas imunes mucosais anti-meningocócicas e podem desviar a predisposição Th1/Th2 das respostas.
BR0407101-8A 2003-01-30 2004-01-30 Vacinas meningocócicas mucosais BRPI0407101A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0302218.3A GB0302218D0 (en) 2003-01-30 2003-01-30 Vaccine formulation & Mucosal delivery
PCT/IB2003/002382 WO2003094834A2 (en) 2002-05-14 2003-05-14 Mucosal vaccines with chitosan adjuvant and meningococcal antigens
PCT/IB2004/000673 WO2004067033A1 (en) 2002-05-14 2004-01-30 Mucosal meningococcal vaccines

Publications (1)

Publication Number Publication Date
BRPI0407101A true BRPI0407101A (pt) 2006-01-24

Family

ID=9952172

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0310062-6A BR0310062A (pt) 2002-05-14 2003-05-14 Vacinas mucosas com adjuvante de quitosana e/ou antìgenos meningocócicos
BR0407101-8A BRPI0407101A (pt) 2003-01-30 2004-01-30 Vacinas meningocócicas mucosais

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0310062-6A BR0310062A (pt) 2002-05-14 2003-05-14 Vacinas mucosas com adjuvante de quitosana e/ou antìgenos meningocócicos

Country Status (13)

Country Link
US (1) US8926992B2 (pt)
EP (2) EP1506008B1 (pt)
JP (4) JP4696260B2 (pt)
CN (1) CN100579580C (pt)
AU (1) AU2003233128B2 (pt)
BR (2) BR0310062A (pt)
CA (1) CA2485992C (pt)
ES (2) ES2328128T3 (pt)
GB (1) GB0302218D0 (pt)
MX (1) MXPA05007886A (pt)
NZ (1) NZ536715A (pt)
RU (2) RU2004136299A (pt)
WO (1) WO2003094834A2 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP1506007B1 (en) * 2002-05-14 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Mucosal combination vaccines for bacterial meningitis
DE60328481D1 (de) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP1587537B1 (en) * 2003-01-30 2012-04-11 Novartis AG Injectable vaccines against multiple meningococcal serogroups
ATE426412T1 (de) * 2003-01-30 2009-04-15 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
AU2011224064A1 (en) * 2003-10-02 2011-10-06 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
CN103405761A (zh) * 2003-10-02 2013-11-27 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗
ATE512670T1 (de) 2004-04-30 2011-07-15 Novartis Vaccines & Diagnostic Meningokokken-konjugat-impfung
GB0500787D0 (en) * 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
AU2012203419B2 (en) * 2005-06-27 2014-06-26 Glaxosmithkline Biologicals S.A. Immunogenic composition
US9931397B2 (en) * 2005-06-27 2018-04-03 Glaxosmithkline Biologicals S.A. Immunogenic composition
US20100150960A1 (en) * 2006-09-22 2010-06-17 The United States Of America, As Represented By The Secretary,Department Of Health And Human Servi Compositions and methods for chitosan enhanced immune response
CA2664157C (en) * 2006-09-29 2015-12-01 Ligocyte Pharmaceuticals, Inc. Norovirus vaccine formulations
WO2009014774A1 (en) * 2007-04-06 2009-01-29 Inviragen, Inc. Methods and compositions for live attenuated viruses
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CA2698397C (en) 2007-09-18 2018-03-27 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
SI2200642T1 (sl) * 2007-10-19 2012-06-29 Novartis Ag Formulacije meningokoknega cepiva
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
EP3056212B1 (en) 2010-09-10 2019-04-03 Wyeth LLC Non-lipidated variants of neisseria meningitidis orf2086 antigens
CN105031637A (zh) 2011-07-11 2015-11-11 武田疫苗股份有限公司 胃肠外诺如病毒疫苗配制剂
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN107056901B (zh) 2012-03-09 2021-05-07 辉瑞公司 脑膜炎双球菌组合物及其方法
KR102103366B1 (ko) * 2012-04-30 2020-04-22 바이오테라, 인크. β-글루칸 면역치료 방법
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3530285B1 (en) * 2016-10-20 2023-08-09 KM Biologics Co., Ltd. METHOD FOR PRODUCING HIB CONJUGATE VACCINE USING PRP WITH
LOWERED MOLECULAR WEIGHT
EP3522856B1 (en) * 2016-11-08 2022-03-23 Colgate-Palmolive Company Oral care compositions
CN110234658B (zh) 2017-01-31 2024-03-12 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
CA3126492A1 (en) * 2019-01-11 2020-07-16 Northwestern University Bioconjugate vaccines synthesis in prokaryotic cell lysates
BR112022023746A2 (pt) * 2020-05-22 2023-02-07 Alberto Riveros Carlos Sistema, método e uso de um determinado medicamento para reduzir a replicação viral na mucosa das vias aéreas

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
BRPI0009163B8 (pt) 1999-03-19 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica e vacina que a compreende
JP2002540076A (ja) * 1999-03-24 2002-11-26 イギリス国 ワクチン組成物
GB9923060D0 (en) 1999-09-29 1999-12-01 Chiron Spa Vaccine
AU783099B2 (en) 2000-01-07 2005-09-22 Rohm Gmbh & Co. Kg Selective activation of a TH1 or TH2 lymphocyte regulated immune response
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
EG24742A (en) 2000-06-29 2010-07-14 Smithkline Beecham Biolog Vaccine composition.
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0029919D0 (en) 2000-12-07 2001-01-24 Chiron Spa Helicobacter pylori prime & boost vaccination
KR100947751B1 (ko) * 2001-01-23 2010-03-18 아벤티스 파스퇴르 다가 수막구균 폴리사카라이드-단백질 접합체 백신
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
ES2399386T3 (es) * 2001-04-05 2013-04-01 Novartis Vaccines And Diagnostics, Inc. Aumento de la inmunidad de las mucosas tras sensibilización parenteral
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
JP4522699B2 (ja) * 2001-10-03 2010-08-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アジュバント化されたＭｅｎｉｎｇｏｃｏｃｃｕｓ組成物
GB0129007D0 (en) 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
DE60331412D1 (de) * 2002-01-14 2010-04-08 Novartis Vaccines & Diagnostic Hiv-vakzine und anwendungsverfahren
JP4267461B2 (ja) * 2002-03-18 2009-05-27 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 有価証券用のホルダ及びこの内容を登録するための方法
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
EP1506007B1 (en) 2002-05-14 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Mucosal combination vaccines for bacterial meningitis

Also Published As

Publication number Publication date
US8926992B2 (en) 2015-01-06
ES2470765T3 (es) 2014-06-24
JP2012046550A (ja) 2012-03-08
MXPA05007886A (es) 2005-09-21
JP4696260B2 (ja) 2011-06-08
JP2005525415A (ja) 2005-08-25
EP1506008B1 (en) 2009-07-22
EP1587538B1 (en) 2014-04-02
RU2005127200A (ru) 2006-06-10
JP2016104813A (ja) 2016-06-09
GB0302218D0 (en) 2003-03-05
AU2003233128A1 (en) 2003-11-11
EP1506008A2 (en) 2005-02-16
ES2328128T3 (es) 2009-11-10
WO2003094834A2 (en) 2003-11-20
WO2003094834A3 (en) 2004-05-21
BR0310062A (pt) 2005-02-15
RU2004136299A (ru) 2006-03-10
NZ536715A (en) 2007-02-23
JP2015061879A (ja) 2015-04-02
AU2003233128B2 (en) 2008-10-09
EP1587538A1 (en) 2005-10-26
CN1767853A (zh) 2006-05-03
CN100579580C (zh) 2010-01-13
US20060051378A1 (en) 2006-03-09
CA2485992C (en) 2013-07-09
RU2349342C2 (ru) 2009-03-20
CA2485992A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
BRPI0407101A (pt) Vacinas meningocócicas mucosais
BRPI0510104A8 (pt) Imunização contra sorogrupo meningocócico y que usa proteínas
WO2004067030A3 (en) Injectable vaccines against multiple meningococcal serogroups
Sanders et al. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines
CR10123A (es) Vacuna.
WO2007026249A3 (en) Multiple vaccination including serogroup c meningococcus
BR0310042A (pt) Vacinas de combinação mucosal para meningite bacteriana
BRPI0408167A (pt) conjugados de polissacarìdeo-proteìna veìculo adesina da superfìcie estafilocócica para imunização contra infecções nosocomiais
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
BRPI0612670B8 (pt) composição imunogênica, vacina a compreendendo e kit de vacina para a administração concomitante ou sequencial
WO2005032583A3 (en) Liquid vaccines for multiple meningococcal serogroups
DE122010000040I1 (de) Solubilisierung von capsulären Polysacchariden
WO2004041157A3 (en) Group b streptococcus vaccine
BRPI0818545A2 (pt) formulações de vacinais meningocócicas
JP2007516219A5 (pt)
BRPI0410341B8 (pt) conjugados de polissacarídeo-proteína derivatizados de meningococos multivalentes e vacina
BRPI0516770A (pt) vacina e conjugados de proteìna - derivados de polissacarìdeo de meningocócico multivalente
WO2022101745A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN101815527A (zh) 用作抵抗空肠弯曲菌的免疫原的荚膜组合物
WO2005007804A3 (en) Anthrax conjugate vaccine and antibodies
BRPI0516372A (pt) conjugados de polissacarìdeo-proteìna derivatizados meningocócicos multivalentes e vacina
Ali et al. Synergistic Effect of Coadministration of Haemophilus influenzae and Neisseria meningitidis Vaccines on Immune Responses to Meningitis in Mouse Model
WO2024201324A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2005023295A3 (en) Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: UNIVERSITEIT LEIDEN (NL) , NOVARTIS VACCINES AND D

Free format text: ALTERADO DE: CHIRON SRL.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2447 DE 28-11-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.